St. Jude Reference #SJ-24-0024
Researchers have derived a new clonal cell line, SJ293TS-DPB (SJ293TS-delta-PKR,- B2M), for the production of lentiviral vectors. This cell line grows in suspension using serum-free media making the production scheme amenable to large scale cGMP manufacturing of lentiviral vectors. The absence of Protein Kinase R in these cells allows for high titer manufacturing of anti-sense lentiviral vectors. In addition, knocking out expression of Beta-2 microglobulin (B2M) prevents transfer of this membrane protein, a key component of MHC-class I molecules, to viral particles. Previous reports have shown that viral particles containing B2M are more immunogenic than B2M-negative particles. Thus, this cell line may be better suited for producing clinical-grade lentiviral particles used for in vivo CAR T manufacturing.
Advantages of the cell line include allowing for high titer anti-sense lentiviral vector production (7-fold higher than wild-type 293T cells), amenable to large-scale cGMP manufacturing of viral vectors, and well-suited to support in vivo CAR-T cell manufacturing.
Granted patents or published applications
Related scientific references
Genetic Alteration of SJ293TS Cells and Modification of Serum-Free Media Enhances Lentiviral Vector Production. Matthew Bauler et al. submitted.
We are currently seeking licensees for this viral vector cell line.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.